data_1j8z_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1j8z _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.18 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 39.4 mm -113.65 96.15 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 104.817 -2.29 . . . . 0.0 104.817 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -145.46 152.85 40.44 Favored 'General case' 0 CA--C 1.558 1.268 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.439 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.23 -85.7 1.21 Allowed Glycine 0 CA--C 1.542 1.765 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.077 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.6 t -74.63 86.58 2.13 Favored 'General case' 0 N--CA 1.493 1.698 1 CA-C-N 136.582 8.81 . . . . 0.0 109.564 -177.202 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.32 -54.93 0.45 Allowed Glycine 0 CA--C 1.546 1.983 0 CA-C-N 114.115 -1.402 . . . . 0.0 109.885 -176.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -77.21 -68.81 0.58 Allowed 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 123.726 0.811 . . . . 0.0 109.94 177.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 60.0 tp -160.14 113.0 2.09 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -52.87 142.02 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.7 m -82.08 95.22 7.39 Favored 'General case' 0 CA--C 1.557 1.223 0 C-N-CA 123.835 0.854 . . . . 0.0 110.102 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 69.9 p -70.15 105.82 3.06 Favored 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 114.926 -1.034 . . . . 0.0 111.207 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.0 p -141.8 102.71 4.21 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 -179.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.294 0 CA-C-O 124.158 1.932 . . . . 0.0 110.836 -179.913 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.199 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.8 mm -126.42 113.02 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 104.806 -2.294 . . . . 0.0 104.806 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -66.18 134.02 51.86 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -89.35 -108.63 1.19 Allowed Glycine 0 CA--C 1.539 1.591 0 CA-C-N 116.381 -0.372 . . . . 0.0 113.692 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.4 t -74.86 86.75 2.25 Favored 'General case' 0 N--CA 1.493 1.693 1 CA-C-N 136.865 8.939 . . . . 0.0 109.587 -176.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 144.12 -51.99 0.62 Allowed Glycine 0 CA--C 1.547 2.053 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.391 -176.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -77.31 -67.12 0.75 Allowed 'General case' 0 CA--C 1.562 1.435 0 C-N-CA 123.856 0.862 . . . . 0.0 110.014 178.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -159.97 108.01 1.7 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 105.646 -1.983 . . . . 0.0 105.646 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.265 2.0 pp -51.43 138.75 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -178.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.2 m -82.01 94.42 7.16 Favored 'General case' 0 CA--C 1.556 1.199 0 CA-C-O 122.008 0.909 . . . . 0.0 110.076 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.7 p -68.84 114.01 6.79 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.776 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 m -143.33 116.27 8.83 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 124.179 1.943 . . . . 0.0 110.698 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.231 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.24 106.87 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 65.5 m95 -138.34 129.8 27.63 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 115.197 -0.91 . . . . 0.0 109.854 -178.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.44 -112.14 0.69 Allowed Glycine 0 CA--C 1.537 1.422 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.5 t -78.8 87.45 4.68 Favored 'General case' 0 N--CA 1.495 1.78 1 CA-C-N 137.737 9.335 . . . . 0.0 109.273 -177.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.21 -51.67 0.75 Allowed Glycine 0 CA--C 1.548 2.098 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.989 -176.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.3 tppp? -70.13 -64.32 0.91 Allowed 'General case' 0 CA--C 1.562 1.419 0 C-N-CA 124.108 0.963 . . . . 0.0 111.427 178.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 50.0 tp -153.6 104.52 2.73 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 105.366 -2.086 . . . . 0.0 105.366 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.252 1.7 pp -53.63 113.44 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 79.0 m -89.91 81.44 6.3 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 121.8 0.81 . . . . 0.0 111.682 -178.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.9 p -83.79 106.91 15.85 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.559 0.744 . . . . 0.0 110.307 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.1 m -81.86 -53.53 6.09 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 118.5 -0.762 . . . . 0.0 112.909 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.218 0 CA-C-O 124.109 1.909 . . . . 0.0 110.608 179.874 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.246 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 10.8 tp -149.91 112.58 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 80.5 m95 -131.89 122.13 25.16 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.183 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.22 -88.74 0.54 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.9 t -59.53 87.99 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 CA-C-N 125.413 3.733 . . . . 0.0 111.695 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 150.43 -54.54 0.48 Allowed Glycine 0 CA--C 1.557 2.682 0 CA-C-N 111.728 -2.487 . . . . 0.0 108.325 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -79.03 -71.16 0.45 Allowed 'General case' 0 CA--C 1.572 1.79 0 C-N-CA 124.523 1.129 . . . . 0.0 109.317 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.2 tp -139.34 102.23 4.44 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 104.523 -2.399 . . . . 0.0 104.523 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.3 pp -33.28 142.14 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.432 0 N-CA-C 119.804 3.261 . . . . 0.0 119.804 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -87.28 80.2 8.29 Favored 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 123.773 0.829 . . . . 0.0 111.804 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 66.9 p -116.01 102.52 9.72 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 p -140.43 102.32 4.31 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.261 0 CA-C-O 124.159 1.933 . . . . 0.0 108.979 -179.934 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.184 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.7 mm -112.67 99.31 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 32.3 m95 -93.46 109.5 21.09 Favored 'General case' 0 CA--C 1.554 1.13 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.065 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 98.24 101.95 2.22 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.0 t -79.64 88.96 5.12 Favored 'General case' 0 N--CA 1.493 1.699 1 CA-C-N 136.211 8.641 . . . . 0.0 108.125 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.56 -50.86 0.67 Allowed Glycine 0 CA--C 1.548 2.104 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.44 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -75.65 -66.92 0.72 Allowed 'General case' 0 CA--C 1.563 1.452 0 C-N-CA 124.028 0.931 . . . . 0.0 108.768 177.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 53.3 tp -167.29 116.44 0.83 Allowed 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.269 2.1 pp -54.92 132.42 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 114.335 1.235 . . . . 0.0 114.335 -178.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 72.0 m -96.39 94.75 7.61 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 123.753 0.821 . . . . 0.0 110.817 -177.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.8 p -71.76 104.44 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.979 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.6 p -141.69 103.65 4.4 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 122.821 1.296 . . . . 0.0 112.646 -179.87 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -99.56 79.18 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 CA-C-O 122.116 0.96 . . . . 0.0 110.859 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -148.41 62.83 1.09 Allowed 'General case' 0 CA--C 1.561 1.378 0 C-N-CA 124.206 1.003 . . . . 0.0 111.18 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 59.22 76.54 0.21 Allowed Glycine 0 N--CA 1.49 2.277 0 CA-C-O 119.038 -0.868 . . . . 0.0 113.613 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -78.8 87.23 4.68 Favored 'General case' 0 N--CA 1.494 1.739 1 CA-C-N 137.246 9.112 . . . . 0.0 109.37 -177.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.22 -49.22 0.78 Allowed Glycine 0 CA--C 1.546 2.004 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.867 -176.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -73.43 -68.26 0.51 Allowed 'General case' 0 CA--C 1.561 1.383 0 C-N-CA 124.074 0.95 . . . . 0.0 109.94 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 61.7 tp -162.65 110.04 1.28 Allowed 'General case' 0 CA--C 1.552 1.047 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.9 pt -51.5 133.41 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -179.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 85.7 m -103.0 83.82 2.27 Favored 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 121.612 0.72 . . . . 0.0 112.181 -178.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.0 t -161.82 122.25 2.61 Favored 'General case' 0 N--CA 1.485 1.289 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.9 m -84.69 -54.05 4.97 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 114.852 -1.067 . . . . 0.0 112.805 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.218 0 CA-C-O 124.18 1.943 . . . . 0.0 108.488 179.774 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.209 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 pp -132.1 105.4 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -159.1 -64.67 0.08 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.471 0.708 . . . . 0.0 112.252 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.91 -90.36 0.47 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.631 -0.588 . . . . 0.0 111.631 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.2 t -79.05 86.16 4.91 Favored 'General case' 0 N--CA 1.496 1.834 1 CA-C-N 134.426 7.83 . . . . 0.0 107.955 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.4 -53.5 0.44 Allowed Glycine 0 CA--C 1.546 2.0 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -175.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -76.12 -69.44 0.5 Allowed 'General case' 0 CA--C 1.564 1.518 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.8 tp -165.12 117.28 1.18 Allowed 'General case' 0 CA--C 1.553 1.063 0 N-CA-C 104.445 -2.428 . . . . 0.0 104.445 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.3 pt -52.9 132.07 15.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 22.6 p -113.65 89.3 3.05 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 121.283 0.564 . . . . 0.0 110.648 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.9 p -81.93 102.64 11.04 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.544 0.737 . . . . 0.0 110.129 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.4 p -140.4 102.31 4.31 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-O 124.306 2.003 . . . . 0.0 110.756 -179.836 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.2 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 40.9 mm -117.19 99.19 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 104.68 -2.341 . . . . 0.0 104.68 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 97.2 m95 -137.68 94.37 2.9 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 173.25 -84.72 0.08 OUTLIER Glycine 0 CA--C 1.537 1.468 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 35.6 t -74.23 85.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.654 1 CA-C-N 136.689 8.859 . . . . 0.0 109.563 -177.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.31 -54.65 0.46 Allowed Glycine 0 CA--C 1.546 1.989 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.092 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -76.95 -68.51 0.6 Allowed 'General case' 0 CA--C 1.564 1.511 0 C-N-CA 123.674 0.789 . . . . 0.0 110.1 178.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.1 tt -157.91 111.13 2.45 Favored 'General case' 0 CA--C 1.555 1.165 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -51.77 140.28 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 N-CA-C 114.773 1.397 . . . . 0.0 114.773 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 8.1 m -82.86 82.48 8.13 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.728 0.775 . . . . 0.0 110.215 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 t -103.79 140.74 37.22 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 124.478 1.111 . . . . 0.0 111.716 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.5 p -97.14 92.58 6.11 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.277 0 CA-C-O 122.961 1.362 . . . . 0.0 109.932 -179.594 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.23 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.6 tp -143.13 106.46 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 53.7 p-90 -158.0 137.56 11.99 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.348 -177.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -108.48 -110.18 3.37 Favored Glycine 0 N--CA 1.481 1.641 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 178.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 35.0 t -74.44 86.28 2.03 Favored 'General case' 0 N--CA 1.493 1.686 1 CA-C-N 135.826 8.466 . . . . 0.0 109.375 -177.211 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.74 -51.37 0.56 Allowed Glycine 0 CA--C 1.547 2.068 0 CA-C-N 114.363 -1.29 . . . . 0.0 110.008 -176.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -77.18 -71.83 0.38 Allowed 'General case' 0 CA--C 1.563 1.467 0 C-N-CA 124.137 0.975 . . . . 0.0 108.765 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 45.6 tp -160.85 107.55 1.48 Allowed 'General case' 0 CA--C 1.557 1.215 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -44.74 142.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -178.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.5 m -86.82 71.32 10.33 Favored 'General case' 0 CA--C 1.566 1.583 0 CA-C-O 122.112 0.958 . . . . 0.0 112.139 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 22.2 p -148.09 -65.74 0.25 Allowed 'General case' 0 CA--C 1.56 1.353 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 67.8 p -81.86 -46.57 13.94 Favored 'General case' 0 CA--C 1.567 1.599 0 C-N-CA 123.976 0.91 . . . . 0.0 111.955 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 CA-C-O 123.072 1.415 . . . . 0.0 108.362 179.262 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.155 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -90.14 78.01 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 CA-C-O 122.183 0.992 . . . . 0.0 110.751 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -92.47 120.59 33.11 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 123.732 0.813 . . . . 0.0 110.66 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.77 91.89 1.76 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.286 -1.926 . . . . 0.0 108.286 178.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.3 t -98.32 84.68 3.27 Favored 'General case' 0 N--CA 1.489 1.516 1 CA-C-N 148.35 14.159 . . . . 0.0 108.562 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 134.63 -48.29 0.95 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.986 -177.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 36.9 mtmm -69.64 -60.53 2.26 Favored 'General case' 0 CA--C 1.561 1.379 0 C-N-CA 124.39 1.076 . . . . 0.0 112.311 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.5 tp -159.55 104.36 1.6 Allowed 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -178.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -52.67 137.06 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.07 88.02 3.57 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 122.167 0.984 . . . . 0.0 112.622 -178.238 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.5 p -131.59 101.11 5.36 Favored 'General case' 0 CA--C 1.554 1.124 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 p -137.94 103.03 4.86 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 122.881 1.324 . . . . 0.0 112.635 -179.834 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.164 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 7.0 tp -143.35 105.07 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 50.7 m95 -106.98 84.19 1.94 Allowed 'General case' 0 CA--C 1.556 1.189 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.44 96.48 0.2 Allowed Glycine 0 N--CA 1.478 1.477 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -178.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.3 t -77.66 85.5 3.98 Favored 'General case' 0 N--CA 1.492 1.659 1 CA-C-N 135.938 8.517 . . . . 0.0 108.679 -178.021 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.36 -51.32 0.52 Allowed Glycine 0 CA--C 1.549 2.174 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.24 -176.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.82 -65.48 0.79 Allowed 'General case' 0 CA--C 1.566 1.57 0 C-N-CA 124.044 0.937 . . . . 0.0 109.488 178.248 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 59.0 tp -155.41 112.09 3.21 Favored 'General case' 0 CA--C 1.553 1.06 0 N-CA-C 102.203 -3.258 . . . . 0.0 102.203 178.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.312 10.9 tp -46.45 103.74 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 N-CA-C 115.91 1.819 . . . . 0.0 115.91 -177.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.0 p -150.05 58.24 0.97 Allowed 'General case' 0 CA--C 1.56 1.356 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.369 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 56.3 p -67.37 -52.6 38.03 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 114.3 1.222 . . . . 0.0 114.3 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 91.7 m -100.43 -58.4 1.91 Allowed 'General case' 0 CA--C 1.566 1.571 0 C-N-CA 124.398 1.079 . . . . 0.0 109.605 178.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 124.133 1.921 . . . . 0.0 109.441 179.267 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.228 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.8 mm -122.09 107.82 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 104.329 -2.471 . . . . 0.0 104.329 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -126.38 117.8 23.71 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 114.98 -88.95 0.49 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . 0.444 ' SG ' ' C ' ' A' ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.9 t -67.95 83.57 0.21 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 123.88 3.036 . . . . 0.0 109.663 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.15 -50.15 0.7 Allowed Glycine 0 CA--C 1.554 2.512 0 CA-C-N 114.047 -1.433 . . . . 0.0 110.0 -175.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 tptt -75.28 -67.11 0.69 Allowed 'General case' 0 CA--C 1.566 1.571 0 CA-C-N 118.079 0.94 . . . . 0.0 110.544 178.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 57.2 tp -157.33 111.52 2.65 Favored 'General case' 0 CA--C 1.555 1.144 0 N-CA-C 104.571 -2.381 . . . . 0.0 104.571 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.259 2.0 pp -52.36 125.54 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 N-CA-C 115.607 1.706 . . . . 0.0 115.607 -177.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 6.1 p -92.57 76.03 5.06 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.915 0.886 . . . . 0.0 110.526 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.2 t -154.95 -36.28 0.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 114.534 1.309 . . . . 0.0 114.534 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 41.8 p -101.9 96.0 6.75 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.2 0 CA-C-O 124.374 2.035 . . . . 0.0 110.698 -179.733 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.184 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.47 109.54 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -125.03 108.15 11.54 Favored 'General case' 0 CA--C 1.554 1.113 0 C-N-CA 124.085 0.954 . . . . 0.0 109.37 -178.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.41 -103.33 0.27 Allowed Glycine 0 N--CA 1.48 1.568 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . 0.464 ' SG ' ' C ' ' A' ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.0 t -67.56 84.04 0.18 Allowed 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 123.846 3.021 . . . . 0.0 109.275 -177.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.47 -51.56 0.6 Allowed Glycine 0 CA--C 1.554 2.492 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.536 -175.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -76.14 -68.16 0.61 Allowed 'General case' 0 CA--C 1.564 1.502 0 C-N-CA 123.987 0.915 . . . . 0.0 110.894 177.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.4 tt -153.39 110.83 3.51 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 104.329 -2.471 . . . . 0.0 104.329 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pp -52.83 119.52 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 N-CA-C 114.881 1.438 . . . . 0.0 114.881 -178.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 7.6 p -89.52 81.46 6.53 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.008 0.923 . . . . 0.0 111.221 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 74.1 p -82.95 103.5 12.45 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.561 0.744 . . . . 0.0 109.89 -179.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.6 p -139.53 102.31 4.43 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.189 0 CA-C-O 124.141 1.924 . . . . 0.0 111.025 -179.964 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.19 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.4 tp -154.42 116.72 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 1.3 p-90 -73.14 145.75 46.16 Favored 'General case' 0 CA--C 1.562 1.441 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.39 -62.53 0.99 Allowed Glycine 0 N--CA 1.485 1.95 0 N-CA-C 116.7 1.44 . . . . 0.0 116.7 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.7 t -77.71 89.52 3.98 Favored 'General case' 0 N--CA 1.493 1.686 1 CA-C-N 136.061 8.573 . . . . 0.0 110.619 -176.217 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.07 -49.94 0.78 Allowed Glycine 0 CA--C 1.544 1.857 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.504 -177.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -71.17 -64.75 0.85 Allowed 'General case' 0 CA--C 1.564 1.503 0 CA-C-N 118.066 0.933 . . . . 0.0 110.381 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -156.41 109.68 2.65 Favored 'General case' 0 CA--C 1.55 0.957 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.9 pt -57.53 127.78 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 71.1 m -95.38 89.67 5.53 Favored 'General case' 0 CA--C 1.551 1.005 0 CA-C-O 121.623 0.725 . . . . 0.0 111.791 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 82.7 p -71.01 -54.51 10.96 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 42.4 p -102.97 -55.17 2.47 Favored 'General case' 0 CA--C 1.564 1.498 0 C-N-CA 124.495 1.118 . . . . 0.0 112.122 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.195 0 CA-C-O 124.351 2.024 . . . . 0.0 110.227 -179.948 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.216 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -92.9 80.04 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 124.044 0.84 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -85.85 95.96 9.61 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.064 0.935 . . . . 0.0 109.725 -179.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.44 -80.55 0.18 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 107.965 -2.054 . . . . 0.0 107.965 -178.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.2 t -77.64 88.61 3.93 Favored 'General case' 0 N--CA 1.491 1.591 1 CA-C-N 135.961 8.528 . . . . 0.0 108.941 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.81 -51.68 0.68 Allowed Glycine 0 CA--C 1.547 2.038 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.075 -176.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 42.3 tptt -72.17 -64.07 1.02 Allowed 'General case' 0 CA--C 1.564 1.496 0 C-N-CA 123.905 0.882 . . . . 0.0 110.73 178.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.7 tp -157.46 109.01 2.33 Favored 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 104.052 -2.573 . . . . 0.0 104.052 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.7 tp -55.46 109.15 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.255 0 C-N-CA 123.381 0.673 . . . . 0.0 112.044 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . 0.274 2.1 p -106.43 64.65 0.66 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -177.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 46.9 p -89.54 102.57 15.25 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.0 p -139.71 101.56 4.23 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 124.185 1.945 . . . . 0.0 109.028 -179.941 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.215 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -94.46 75.02 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 CA-C-O 122.401 1.096 . . . . 0.0 111.572 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . 0.3 28.5 p-90 -146.67 -101.38 0.09 Allowed 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.61 -64.51 1.32 Allowed Glycine 0 CA--C 1.55 2.224 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 177.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.2 t -74.9 84.17 2.21 Favored 'General case' 0 N--CA 1.494 1.728 1 CA-C-N 135.766 8.439 . . . . 0.0 109.281 -178.001 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.76 -53.69 0.44 Allowed Glycine 0 CA--C 1.547 2.05 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -176.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.8 -70.93 0.45 Allowed 'General case' 0 CA--C 1.564 1.494 0 C-N-CA 123.854 0.861 . . . . 0.0 109.403 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.2 tt -158.74 112.65 2.42 Favored 'General case' 0 CA--C 1.556 1.178 0 N-CA-C 105.031 -2.211 . . . . 0.0 105.031 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.5 pt -50.26 142.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 9.8 m -85.39 89.36 7.66 Favored 'General case' 0 CA--C 1.559 1.321 0 CA-C-O 121.874 0.845 . . . . 0.0 109.651 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 68.3 p -74.95 105.65 6.08 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.693 0.797 . . . . 0.0 110.419 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.6 p -140.24 102.34 4.34 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 124.311 2.005 . . . . 0.0 110.662 -179.866 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.143 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -92.11 61.83 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 99.3 m95 -150.78 88.78 1.5 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.99 90.72 0.16 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -178.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.1 t -98.4 83.54 3.06 Favored 'General case' 0 N--CA 1.489 1.513 1 CA-C-N 147.854 13.934 . . . . 0.0 107.856 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.2 -46.89 0.93 Allowed Glycine 0 CA--C 1.549 2.177 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.798 -177.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -69.45 -65.33 0.73 Allowed 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 124.541 1.137 . . . . 0.0 111.385 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.3 tp -155.28 105.85 2.53 Favored 'General case' 0 CA--C 1.555 1.135 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -179.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 tp -52.22 129.52 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.295 0 C-N-CA 123.907 0.883 . . . . 0.0 112.993 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 2.7 m -75.32 71.08 2.28 Favored 'General case' 0 CA--C 1.569 1.697 0 CA-C-O 122.231 1.015 . . . . 0.0 113.503 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.0 p -143.65 144.39 31.87 Favored 'General case' 0 CA--C 1.56 1.334 0 C-N-CA 125.054 1.341 . . . . 0.0 108.396 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.3 p -83.23 93.13 7.61 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 122.33 1.062 . . . . 0.0 109.508 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-N 114.127 -1.397 . . . . 0.0 109.847 -179.625 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.23 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.61 95.19 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 12.9 m0 -99.77 88.27 3.76 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.68 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.44 84.08 0.04 OUTLIER Glycine 0 N--CA 1.48 1.628 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.7 t -78.29 88.39 4.33 Favored 'General case' 0 N--CA 1.495 1.785 1 CA-C-N 134.772 7.987 . . . . 0.0 108.219 -178.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.27 -51.11 0.56 Allowed Glycine 0 CA--C 1.546 2.026 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -176.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -75.79 -70.74 0.42 Allowed 'General case' 0 CA--C 1.563 1.458 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.0 tt -166.51 116.54 0.94 Allowed 'General case' 0 CA--C 1.554 1.098 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.254 2.1 pp -52.83 134.0 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 27.4 p -115.62 101.0 8.45 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.126 0.489 . . . . 0.0 111.537 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 67.6 p -81.17 100.34 9.03 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.4 p -139.59 103.34 4.67 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -178.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.302 0 CA-C-O 122.901 1.334 . . . . 0.0 112.52 -179.833 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.232 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -90.16 76.11 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 CA-C-O 122.165 0.983 . . . . 0.0 111.31 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 77.8 m95 -129.24 97.89 4.73 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 105.216 -2.142 . . . . 0.0 105.216 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.26 110.13 3.42 Favored Glycine 0 CA--C 1.54 1.636 0 N-CA-C 106.357 -2.697 . . . . 0.0 106.357 -176.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.7 t -79.13 89.23 4.83 Favored 'General case' 0 N--CA 1.492 1.665 1 CA-C-N 135.539 8.336 . . . . 0.0 108.427 -177.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.42 -53.2 0.53 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -176.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -75.42 -68.78 0.53 Allowed 'General case' 0 CA--C 1.563 1.461 0 C-N-CA 123.616 0.766 . . . . 0.0 109.37 177.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 64.8 tp -166.08 117.39 1.03 Allowed 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 105.33 -2.1 . . . . 0.0 105.33 -179.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.4 pt -53.87 132.9 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 C-N-CA 123.092 0.557 . . . . 0.0 112.497 179.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 31.8 p -111.75 90.18 3.27 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.293 0.568 . . . . 0.0 111.529 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.4 p -83.94 101.39 11.66 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.483 0.713 . . . . 0.0 109.503 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.9 p -139.89 101.5 4.19 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.27 0 CA-C-O 122.829 1.299 . . . . 0.0 109.822 179.988 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.217 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.0 pp -95.19 99.1 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.563 1.472 0 CA-C-O 123.247 1.499 . . . . 0.0 108.761 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -166.35 -31.28 0.03 OUTLIER 'General case' 0 CA--C 1.567 1.615 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 175.59 -65.15 0.1 OUTLIER Glycine 0 CA--C 1.543 1.811 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -177.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.5 t -78.31 85.82 4.43 Favored 'General case' 0 N--CA 1.492 1.667 1 CA-C-N 136.325 8.693 . . . . 0.0 108.694 -178.45 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.07 -51.48 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 CA-C-N 114.465 -1.243 . . . . 0.0 110.967 -176.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.5 tppt? -73.2 -67.74 0.55 Allowed 'General case' 0 CA--C 1.567 1.607 0 C-N-CA 124.311 1.045 . . . . 0.0 110.173 177.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 tt -153.68 113.74 3.91 Favored 'General case' 0 CA--C 1.553 1.071 0 N-CA-C 101.524 -3.509 . . . . 0.0 101.524 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.311 11.0 tp -50.47 102.77 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 N-CA-C 115.14 1.533 . . . . 0.0 115.14 -177.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.7 p -148.42 52.8 1.0 Allowed 'General case' 0 CA--C 1.562 1.409 0 CA-C-N 114.37 -1.286 . . . . 0.0 112.984 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 74.3 p -96.95 111.24 23.54 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 121.326 -0.859 . . . . 0.0 109.653 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.6 m -141.67 117.35 10.36 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-N 113.894 -1.503 . . . . 0.0 112.427 -179.944 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.308 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -94.21 70.09 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 124.046 0.841 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -144.2 120.79 11.1 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.716 0.807 . . . . 0.0 109.159 -178.685 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -83.24 0.69 Allowed Glycine 0 N--CA 1.48 1.62 0 CA-C-N 116.343 -0.39 . . . . 0.0 112.789 -179.9 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.2 t -78.91 90.77 4.74 Favored 'General case' 0 N--CA 1.493 1.706 1 CA-C-N 134.052 7.66 . . . . 0.0 107.841 -178.323 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 149.52 -53.68 0.51 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -75.23 -68.86 0.51 Allowed 'General case' 0 CA--C 1.566 1.561 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.481 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.8 tp -167.04 117.82 0.89 Allowed 'General case' 0 CA--C 1.554 1.107 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -53.95 133.73 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -179.599 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 29.5 p -111.72 99.2 7.96 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 121.181 0.515 . . . . 0.0 110.624 -177.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 67.2 p -77.56 102.74 7.11 Favored 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 123.467 0.707 . . . . 0.0 110.437 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.5 p -140.84 102.26 4.24 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.036 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 CA-C-O 122.992 1.377 . . . . 0.0 111.855 -179.9 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.199 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.54 106.89 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 . . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 77.7 m95 -138.1 107.46 6.13 Favored 'General case' 0 CA--C 1.555 1.14 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.897 -179.039 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.43 84.43 0.83 Allowed Glycine 0 N--CA 1.484 1.877 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.2 t -78.77 88.65 4.62 Favored 'General case' 0 N--CA 1.494 1.771 1 CA-C-N 135.162 8.165 . . . . 0.0 108.152 -178.262 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.62 -50.57 0.62 Allowed Glycine 0 CA--C 1.548 2.111 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 -176.133 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -74.9 -70.81 0.39 Allowed 'General case' 0 CA--C 1.563 1.461 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.256 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.5 tp -169.08 117.88 0.67 Allowed 'General case' 0 CA--C 1.554 1.103 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 179.796 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.254 2.6 pp -50.94 135.91 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.454 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 19.9 p -123.88 109.17 13.27 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.345 0.593 . . . . 0.0 111.47 -177.268 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 77.1 p -81.7 100.02 9.25 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.273 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 26.4 m -79.37 -52.13 8.49 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -179.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.186 0 CA-C-O 124.366 2.031 . . . . 0.0 110.333 179.946 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.208 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.52 98.5 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 . . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 41.0 m95 -100.34 107.54 19.34 Favored 'General case' 0 CA--C 1.553 1.087 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.851 -178.32 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.1 84.69 0.79 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 178.271 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.5 t -78.5 88.89 4.45 Favored 'General case' 0 N--CA 1.494 1.728 1 CA-C-N 136.843 8.929 . . . . 0.0 108.524 -177.817 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.57 -52.96 0.68 Allowed Glycine 0 CA--C 1.548 2.133 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.644 -176.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -72.81 -62.27 1.51 Allowed 'General case' 0 CA--C 1.563 1.466 0 C-N-CA 123.916 0.886 . . . . 0.0 110.837 178.233 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.6 tt -158.73 110.04 2.14 Favored 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 -179.775 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.7 pp -55.65 115.62 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -179.512 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 80.0 m -89.7 82.66 6.27 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 121.796 0.808 . . . . 0.0 112.265 -177.771 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 66.7 p -84.39 108.25 17.11 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.571 0.749 . . . . 0.0 109.737 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.1 m -141.02 116.18 9.92 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.898 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 124.181 1.943 . . . . 0.0 110.739 179.963 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.16 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -84.24 78.51 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 124.093 0.871 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 8.0 m0 -125.01 116.92 22.9 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.839 0.855 . . . . 0.0 109.898 -177.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.96 80.77 1.09 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 111.745 -0.542 . . . . 0.0 111.745 -179.241 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.7 t -79.11 89.59 4.83 Favored 'General case' 0 N--CA 1.493 1.706 1 CA-C-N 134.808 8.004 . . . . 0.0 107.845 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.31 -52.19 0.56 Allowed Glycine 0 CA--C 1.546 2.004 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.054 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -75.13 -70.12 0.43 Allowed 'General case' 0 CA--C 1.564 1.486 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 177.357 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 66.8 tp -167.96 118.04 0.8 Allowed 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.899 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 pt -52.4 133.12 14.5 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 N-CA-C 113.032 0.753 . . . . 0.0 113.032 -179.673 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 24.0 p -114.88 86.93 2.54 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 121.551 0.691 . . . . 0.0 111.724 -177.906 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 77.5 p -81.65 -57.13 3.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.712 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 60.3 p -98.66 -49.32 4.65 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 124.429 1.092 . . . . 0.0 113.356 -179.454 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 124.321 2.01 . . . . 0.0 111.403 -179.827 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.18 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 39.4 mm -113.65 96.15 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 104.817 -2.29 . . . . 0.0 104.817 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -145.46 152.85 40.44 Favored 'General case' 0 CA--C 1.558 1.268 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.439 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.23 -85.7 1.21 Allowed Glycine 0 CA--C 1.542 1.765 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.077 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.6 t -74.63 86.58 2.13 Favored 'General case' 0 N--CA 1.493 1.698 1 CA-C-N 136.582 8.81 . . . . 0.0 109.564 -177.202 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.32 -54.93 0.45 Allowed Glycine 0 CA--C 1.546 1.983 0 CA-C-N 114.115 -1.402 . . . . 0.0 109.885 -176.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -77.21 -68.81 0.58 Allowed 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 123.726 0.811 . . . . 0.0 109.94 177.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 60.0 tp -160.14 113.0 2.09 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -52.87 142.02 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.7 m -82.08 95.22 7.39 Favored 'General case' 0 CA--C 1.557 1.223 0 C-N-CA 123.835 0.854 . . . . 0.0 110.102 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 69.9 p -70.15 105.82 3.06 Favored 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 114.926 -1.034 . . . . 0.0 111.207 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.0 p -141.8 102.71 4.21 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 -179.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.294 0 CA-C-O 124.158 1.932 . . . . 0.0 110.836 -179.913 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.199 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.8 mm -126.42 113.02 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 104.806 -2.294 . . . . 0.0 104.806 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -66.18 134.02 51.86 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -89.35 -108.63 1.19 Allowed Glycine 0 CA--C 1.539 1.591 0 CA-C-N 116.381 -0.372 . . . . 0.0 113.692 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.4 t -74.86 86.75 2.25 Favored 'General case' 0 N--CA 1.493 1.693 1 CA-C-N 136.865 8.939 . . . . 0.0 109.587 -176.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 144.12 -51.99 0.62 Allowed Glycine 0 CA--C 1.547 2.053 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.391 -176.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -77.31 -67.12 0.75 Allowed 'General case' 0 CA--C 1.562 1.435 0 C-N-CA 123.856 0.862 . . . . 0.0 110.014 178.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -159.97 108.01 1.7 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 105.646 -1.983 . . . . 0.0 105.646 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.265 2.0 pp -51.43 138.75 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -178.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.2 m -82.01 94.42 7.16 Favored 'General case' 0 CA--C 1.556 1.199 0 CA-C-O 122.008 0.909 . . . . 0.0 110.076 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.7 p -68.84 114.01 6.79 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.776 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 m -143.33 116.27 8.83 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 124.179 1.943 . . . . 0.0 110.698 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.231 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.24 106.87 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 65.5 m95 -138.34 129.8 27.63 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 115.197 -0.91 . . . . 0.0 109.854 -178.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.44 -112.14 0.69 Allowed Glycine 0 CA--C 1.537 1.422 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.5 t -78.8 87.45 4.68 Favored 'General case' 0 N--CA 1.495 1.78 1 CA-C-N 137.737 9.335 . . . . 0.0 109.273 -177.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.21 -51.67 0.75 Allowed Glycine 0 CA--C 1.548 2.098 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.989 -176.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.3 tppp? -70.13 -64.32 0.91 Allowed 'General case' 0 CA--C 1.562 1.419 0 C-N-CA 124.108 0.963 . . . . 0.0 111.427 178.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 50.0 tp -153.6 104.52 2.73 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 105.366 -2.086 . . . . 0.0 105.366 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.252 1.7 pp -53.63 113.44 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 79.0 m -89.91 81.44 6.3 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 121.8 0.81 . . . . 0.0 111.682 -178.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.9 p -83.79 106.91 15.85 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.559 0.744 . . . . 0.0 110.307 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.1 m -81.86 -53.53 6.09 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 118.5 -0.762 . . . . 0.0 112.909 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.218 0 CA-C-O 124.109 1.909 . . . . 0.0 110.608 179.874 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.246 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 10.8 tp -149.91 112.58 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 80.5 m95 -131.89 122.13 25.16 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.183 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.22 -88.74 0.54 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.9 t -59.53 87.99 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 CA-C-N 125.413 3.733 . . . . 0.0 111.695 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 150.43 -54.54 0.48 Allowed Glycine 0 CA--C 1.557 2.682 0 CA-C-N 111.728 -2.487 . . . . 0.0 108.325 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -79.03 -71.16 0.45 Allowed 'General case' 0 CA--C 1.572 1.79 0 C-N-CA 124.523 1.129 . . . . 0.0 109.317 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.2 tp -139.34 102.23 4.44 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 104.523 -2.399 . . . . 0.0 104.523 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.3 pp -33.28 142.14 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.432 0 N-CA-C 119.804 3.261 . . . . 0.0 119.804 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -87.28 80.2 8.29 Favored 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 123.773 0.829 . . . . 0.0 111.804 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 66.9 p -116.01 102.52 9.72 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 p -140.43 102.32 4.31 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.261 0 CA-C-O 124.159 1.933 . . . . 0.0 108.979 -179.934 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.184 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.7 mm -112.67 99.31 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 32.3 m95 -93.46 109.5 21.09 Favored 'General case' 0 CA--C 1.554 1.13 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.065 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 98.24 101.95 2.22 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.0 t -79.64 88.96 5.12 Favored 'General case' 0 N--CA 1.493 1.699 1 CA-C-N 136.211 8.641 . . . . 0.0 108.125 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.56 -50.86 0.67 Allowed Glycine 0 CA--C 1.548 2.104 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.44 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -75.65 -66.92 0.72 Allowed 'General case' 0 CA--C 1.563 1.452 0 C-N-CA 124.028 0.931 . . . . 0.0 108.768 177.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 53.3 tp -167.29 116.44 0.83 Allowed 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.269 2.1 pp -54.92 132.42 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 114.335 1.235 . . . . 0.0 114.335 -178.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 72.0 m -96.39 94.75 7.61 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 123.753 0.821 . . . . 0.0 110.817 -177.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.8 p -71.76 104.44 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.979 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.6 p -141.69 103.65 4.4 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 122.821 1.296 . . . . 0.0 112.646 -179.87 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -99.56 79.18 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 CA-C-O 122.116 0.96 . . . . 0.0 110.859 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -148.41 62.83 1.09 Allowed 'General case' 0 CA--C 1.561 1.378 0 C-N-CA 124.206 1.003 . . . . 0.0 111.18 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 59.22 76.54 0.21 Allowed Glycine 0 N--CA 1.49 2.277 0 CA-C-O 119.038 -0.868 . . . . 0.0 113.613 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -78.8 87.23 4.68 Favored 'General case' 0 N--CA 1.494 1.739 1 CA-C-N 137.246 9.112 . . . . 0.0 109.37 -177.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.22 -49.22 0.78 Allowed Glycine 0 CA--C 1.546 2.004 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.867 -176.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -73.43 -68.26 0.51 Allowed 'General case' 0 CA--C 1.561 1.383 0 C-N-CA 124.074 0.95 . . . . 0.0 109.94 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 61.7 tp -162.65 110.04 1.28 Allowed 'General case' 0 CA--C 1.552 1.047 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.9 pt -51.5 133.41 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -179.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 85.7 m -103.0 83.82 2.27 Favored 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 121.612 0.72 . . . . 0.0 112.181 -178.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.0 t -161.82 122.25 2.61 Favored 'General case' 0 N--CA 1.485 1.289 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.9 m -84.69 -54.05 4.97 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 114.852 -1.067 . . . . 0.0 112.805 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.218 0 CA-C-O 124.18 1.943 . . . . 0.0 108.488 179.774 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.209 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 pp -132.1 105.4 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -159.1 -64.67 0.08 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.471 0.708 . . . . 0.0 112.252 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.91 -90.36 0.47 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.631 -0.588 . . . . 0.0 111.631 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.2 t -79.05 86.16 4.91 Favored 'General case' 0 N--CA 1.496 1.834 1 CA-C-N 134.426 7.83 . . . . 0.0 107.955 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.4 -53.5 0.44 Allowed Glycine 0 CA--C 1.546 2.0 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -175.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -76.12 -69.44 0.5 Allowed 'General case' 0 CA--C 1.564 1.518 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.8 tp -165.12 117.28 1.18 Allowed 'General case' 0 CA--C 1.553 1.063 0 N-CA-C 104.445 -2.428 . . . . 0.0 104.445 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.3 pt -52.9 132.07 15.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 22.6 p -113.65 89.3 3.05 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 121.283 0.564 . . . . 0.0 110.648 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.9 p -81.93 102.64 11.04 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.544 0.737 . . . . 0.0 110.129 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.4 p -140.4 102.31 4.31 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-O 124.306 2.003 . . . . 0.0 110.756 -179.836 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.2 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 40.9 mm -117.19 99.19 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 104.68 -2.341 . . . . 0.0 104.68 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 97.2 m95 -137.68 94.37 2.9 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 173.25 -84.72 0.08 OUTLIER Glycine 0 CA--C 1.537 1.468 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 35.6 t -74.23 85.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.654 1 CA-C-N 136.689 8.859 . . . . 0.0 109.563 -177.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.31 -54.65 0.46 Allowed Glycine 0 CA--C 1.546 1.989 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.092 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -76.95 -68.51 0.6 Allowed 'General case' 0 CA--C 1.564 1.511 0 C-N-CA 123.674 0.789 . . . . 0.0 110.1 178.219 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.1 tt -157.91 111.13 2.45 Favored 'General case' 0 CA--C 1.555 1.165 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -51.77 140.28 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 N-CA-C 114.773 1.397 . . . . 0.0 114.773 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 8.1 m -82.86 82.48 8.13 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.728 0.775 . . . . 0.0 110.215 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 t -103.79 140.74 37.22 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 124.478 1.111 . . . . 0.0 111.716 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.5 p -97.14 92.58 6.11 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.277 0 CA-C-O 122.961 1.362 . . . . 0.0 109.932 -179.594 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.23 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.6 tp -143.13 106.46 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 53.7 p-90 -158.0 137.56 11.99 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.348 -177.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -108.48 -110.18 3.37 Favored Glycine 0 N--CA 1.481 1.641 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 178.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 35.0 t -74.44 86.28 2.03 Favored 'General case' 0 N--CA 1.493 1.686 1 CA-C-N 135.826 8.466 . . . . 0.0 109.375 -177.211 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.74 -51.37 0.56 Allowed Glycine 0 CA--C 1.547 2.068 0 CA-C-N 114.363 -1.29 . . . . 0.0 110.008 -176.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -77.18 -71.83 0.38 Allowed 'General case' 0 CA--C 1.563 1.467 0 C-N-CA 124.137 0.975 . . . . 0.0 108.765 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 45.6 tp -160.85 107.55 1.48 Allowed 'General case' 0 CA--C 1.557 1.215 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -44.74 142.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -178.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.5 m -86.82 71.32 10.33 Favored 'General case' 0 CA--C 1.566 1.583 0 CA-C-O 122.112 0.958 . . . . 0.0 112.139 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 22.2 p -148.09 -65.74 0.25 Allowed 'General case' 0 CA--C 1.56 1.353 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 67.8 p -81.86 -46.57 13.94 Favored 'General case' 0 CA--C 1.567 1.599 0 C-N-CA 123.976 0.91 . . . . 0.0 111.955 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 CA-C-O 123.072 1.415 . . . . 0.0 108.362 179.262 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.155 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -90.14 78.01 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 CA-C-O 122.183 0.992 . . . . 0.0 110.751 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -92.47 120.59 33.11 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 123.732 0.813 . . . . 0.0 110.66 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.77 91.89 1.76 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.286 -1.926 . . . . 0.0 108.286 178.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.3 t -98.32 84.68 3.27 Favored 'General case' 0 N--CA 1.489 1.516 1 CA-C-N 148.35 14.159 . . . . 0.0 108.562 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 134.63 -48.29 0.95 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.986 -177.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 36.9 mtmm -69.64 -60.53 2.26 Favored 'General case' 0 CA--C 1.561 1.379 0 C-N-CA 124.39 1.076 . . . . 0.0 112.311 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.5 tp -159.55 104.36 1.6 Allowed 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -178.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -52.67 137.06 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.07 88.02 3.57 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 122.167 0.984 . . . . 0.0 112.622 -178.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.5 p -131.59 101.11 5.36 Favored 'General case' 0 CA--C 1.554 1.124 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 p -137.94 103.03 4.86 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 122.881 1.324 . . . . 0.0 112.635 -179.834 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.164 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 7.0 tp -143.35 105.07 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 50.7 m95 -106.98 84.19 1.94 Allowed 'General case' 0 CA--C 1.556 1.189 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.44 96.48 0.2 Allowed Glycine 0 N--CA 1.478 1.477 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -178.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.3 t -77.66 85.5 3.98 Favored 'General case' 0 N--CA 1.492 1.659 1 CA-C-N 135.938 8.517 . . . . 0.0 108.679 -178.021 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.36 -51.32 0.52 Allowed Glycine 0 CA--C 1.549 2.174 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.24 -176.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.82 -65.48 0.79 Allowed 'General case' 0 CA--C 1.566 1.57 0 C-N-CA 124.044 0.937 . . . . 0.0 109.488 178.248 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 59.0 tp -155.41 112.09 3.21 Favored 'General case' 0 CA--C 1.553 1.06 0 N-CA-C 102.203 -3.258 . . . . 0.0 102.203 178.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.312 10.9 tp -46.45 103.74 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 N-CA-C 115.91 1.819 . . . . 0.0 115.91 -177.352 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.0 p -150.05 58.24 0.97 Allowed 'General case' 0 CA--C 1.56 1.356 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.369 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 56.3 p -67.37 -52.6 38.03 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 114.3 1.222 . . . . 0.0 114.3 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 91.7 m -100.43 -58.4 1.91 Allowed 'General case' 0 CA--C 1.566 1.571 0 C-N-CA 124.398 1.079 . . . . 0.0 109.605 178.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 124.133 1.921 . . . . 0.0 109.441 179.267 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.228 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.8 mm -122.09 107.82 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 104.329 -2.471 . . . . 0.0 104.329 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -126.38 117.8 23.71 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 114.98 -88.95 0.49 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' BCX . . . . . 0.444 ' SG ' ' C ' ' A' ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.9 t -67.95 83.57 0.21 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 123.88 3.036 . . . . 0.0 109.663 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.15 -50.15 0.7 Allowed Glycine 0 CA--C 1.554 2.512 0 CA-C-N 114.047 -1.433 . . . . 0.0 110.0 -175.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 tptt -75.28 -67.11 0.69 Allowed 'General case' 0 CA--C 1.566 1.571 0 CA-C-N 118.079 0.94 . . . . 0.0 110.544 178.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 57.2 tp -157.33 111.52 2.65 Favored 'General case' 0 CA--C 1.555 1.144 0 N-CA-C 104.571 -2.381 . . . . 0.0 104.571 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.259 2.0 pp -52.36 125.54 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 N-CA-C 115.607 1.706 . . . . 0.0 115.607 -177.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 6.1 p -92.57 76.03 5.06 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.915 0.886 . . . . 0.0 110.526 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.2 t -154.95 -36.28 0.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 114.534 1.309 . . . . 0.0 114.534 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 41.8 p -101.9 96.0 6.75 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.2 0 CA-C-O 124.374 2.035 . . . . 0.0 110.698 -179.733 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.184 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.47 109.54 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -125.03 108.15 11.54 Favored 'General case' 0 CA--C 1.554 1.113 0 C-N-CA 124.085 0.954 . . . . 0.0 109.37 -178.451 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.41 -103.33 0.27 Allowed Glycine 0 N--CA 1.48 1.568 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' BCX . . . . . 0.464 ' SG ' ' C ' ' A' ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.0 t -67.56 84.04 0.18 Allowed 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 123.846 3.021 . . . . 0.0 109.275 -177.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.47 -51.56 0.6 Allowed Glycine 0 CA--C 1.554 2.492 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.536 -175.219 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -76.14 -68.16 0.61 Allowed 'General case' 0 CA--C 1.564 1.502 0 C-N-CA 123.987 0.915 . . . . 0.0 110.894 177.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.4 tt -153.39 110.83 3.51 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 104.329 -2.471 . . . . 0.0 104.329 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pp -52.83 119.52 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 N-CA-C 114.881 1.438 . . . . 0.0 114.881 -178.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 7.6 p -89.52 81.46 6.53 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.008 0.923 . . . . 0.0 111.221 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 74.1 p -82.95 103.5 12.45 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.561 0.744 . . . . 0.0 109.89 -179.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.6 p -139.53 102.31 4.43 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.189 0 CA-C-O 124.141 1.924 . . . . 0.0 111.025 -179.964 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.19 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.4 tp -154.42 116.72 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 1.3 p-90 -73.14 145.75 46.16 Favored 'General case' 0 CA--C 1.562 1.441 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.39 -62.53 0.99 Allowed Glycine 0 N--CA 1.485 1.95 0 N-CA-C 116.7 1.44 . . . . 0.0 116.7 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.7 t -77.71 89.52 3.98 Favored 'General case' 0 N--CA 1.493 1.686 1 CA-C-N 136.061 8.573 . . . . 0.0 110.619 -176.217 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.07 -49.94 0.78 Allowed Glycine 0 CA--C 1.544 1.857 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.504 -177.742 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -71.17 -64.75 0.85 Allowed 'General case' 0 CA--C 1.564 1.503 0 CA-C-N 118.066 0.933 . . . . 0.0 110.381 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -156.41 109.68 2.65 Favored 'General case' 0 CA--C 1.55 0.957 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.9 pt -57.53 127.78 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 71.1 m -95.38 89.67 5.53 Favored 'General case' 0 CA--C 1.551 1.005 0 CA-C-O 121.623 0.725 . . . . 0.0 111.791 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 82.7 p -71.01 -54.51 10.96 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 42.4 p -102.97 -55.17 2.47 Favored 'General case' 0 CA--C 1.564 1.498 0 C-N-CA 124.495 1.118 . . . . 0.0 112.122 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.195 0 CA-C-O 124.351 2.024 . . . . 0.0 110.227 -179.948 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.216 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -92.9 80.04 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 124.044 0.84 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -85.85 95.96 9.61 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.064 0.935 . . . . 0.0 109.725 -179.112 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.44 -80.55 0.18 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 107.965 -2.054 . . . . 0.0 107.965 -178.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.2 t -77.64 88.61 3.93 Favored 'General case' 0 N--CA 1.491 1.591 1 CA-C-N 135.961 8.528 . . . . 0.0 108.941 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.81 -51.68 0.68 Allowed Glycine 0 CA--C 1.547 2.038 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.075 -176.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 42.3 tptt -72.17 -64.07 1.02 Allowed 'General case' 0 CA--C 1.564 1.496 0 C-N-CA 123.905 0.882 . . . . 0.0 110.73 178.27 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.7 tp -157.46 109.01 2.33 Favored 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 104.052 -2.573 . . . . 0.0 104.052 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.7 tp -55.46 109.15 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.255 0 C-N-CA 123.381 0.673 . . . . 0.0 112.044 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . 0.274 2.1 p -106.43 64.65 0.66 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -177.755 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 46.9 p -89.54 102.57 15.25 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.0 p -139.71 101.56 4.23 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 124.185 1.945 . . . . 0.0 109.028 -179.941 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.215 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -94.46 75.02 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 CA-C-O 122.401 1.096 . . . . 0.0 111.572 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . 0.3 28.5 p-90 -146.67 -101.38 0.09 Allowed 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.61 -64.51 1.32 Allowed Glycine 0 CA--C 1.55 2.224 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 177.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.2 t -74.9 84.17 2.21 Favored 'General case' 0 N--CA 1.494 1.728 1 CA-C-N 135.766 8.439 . . . . 0.0 109.281 -178.001 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.76 -53.69 0.44 Allowed Glycine 0 CA--C 1.547 2.05 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -176.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.8 -70.93 0.45 Allowed 'General case' 0 CA--C 1.564 1.494 0 C-N-CA 123.854 0.861 . . . . 0.0 109.403 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.2 tt -158.74 112.65 2.42 Favored 'General case' 0 CA--C 1.556 1.178 0 N-CA-C 105.031 -2.211 . . . . 0.0 105.031 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.5 pt -50.26 142.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 9.8 m -85.39 89.36 7.66 Favored 'General case' 0 CA--C 1.559 1.321 0 CA-C-O 121.874 0.845 . . . . 0.0 109.651 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 68.3 p -74.95 105.65 6.08 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.693 0.797 . . . . 0.0 110.419 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.6 p -140.24 102.34 4.34 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 124.311 2.005 . . . . 0.0 110.662 -179.866 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.143 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -92.11 61.83 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 99.3 m95 -150.78 88.78 1.5 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 179.658 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.99 90.72 0.16 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -178.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.1 t -98.4 83.54 3.06 Favored 'General case' 0 N--CA 1.489 1.513 1 CA-C-N 147.854 13.934 . . . . 0.0 107.856 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.2 -46.89 0.93 Allowed Glycine 0 CA--C 1.549 2.177 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.798 -177.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -69.45 -65.33 0.73 Allowed 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 124.541 1.137 . . . . 0.0 111.385 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.3 tp -155.28 105.85 2.53 Favored 'General case' 0 CA--C 1.555 1.135 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -179.128 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 tp -52.22 129.52 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.295 0 C-N-CA 123.907 0.883 . . . . 0.0 112.993 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 2.7 m -75.32 71.08 2.28 Favored 'General case' 0 CA--C 1.569 1.697 0 CA-C-O 122.231 1.015 . . . . 0.0 113.503 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.0 p -143.65 144.39 31.87 Favored 'General case' 0 CA--C 1.56 1.334 0 C-N-CA 125.054 1.341 . . . . 0.0 108.396 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.3 p -83.23 93.13 7.61 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 122.33 1.062 . . . . 0.0 109.508 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-N 114.127 -1.397 . . . . 0.0 109.847 -179.625 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.23 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.61 95.19 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 12.9 m0 -99.77 88.27 3.76 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.68 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.44 84.08 0.04 OUTLIER Glycine 0 N--CA 1.48 1.628 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.7 t -78.29 88.39 4.33 Favored 'General case' 0 N--CA 1.495 1.785 1 CA-C-N 134.772 7.987 . . . . 0.0 108.219 -178.1 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.27 -51.11 0.56 Allowed Glycine 0 CA--C 1.546 2.026 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -176.222 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -75.79 -70.74 0.42 Allowed 'General case' 0 CA--C 1.563 1.458 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.374 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.0 tt -166.51 116.54 0.94 Allowed 'General case' 0 CA--C 1.554 1.098 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.254 2.1 pp -52.83 134.0 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 27.4 p -115.62 101.0 8.45 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.126 0.489 . . . . 0.0 111.537 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 67.6 p -81.17 100.34 9.03 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.4 p -139.59 103.34 4.67 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -178.688 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.302 0 CA-C-O 122.901 1.334 . . . . 0.0 112.52 -179.833 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.232 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -90.16 76.11 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 CA-C-O 122.165 0.983 . . . . 0.0 111.31 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 77.8 m95 -129.24 97.89 4.73 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 105.216 -2.142 . . . . 0.0 105.216 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.26 110.13 3.42 Favored Glycine 0 CA--C 1.54 1.636 0 N-CA-C 106.357 -2.697 . . . . 0.0 106.357 -176.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.7 t -79.13 89.23 4.83 Favored 'General case' 0 N--CA 1.492 1.665 1 CA-C-N 135.539 8.336 . . . . 0.0 108.427 -177.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.42 -53.2 0.53 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -176.596 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -75.42 -68.78 0.53 Allowed 'General case' 0 CA--C 1.563 1.461 0 C-N-CA 123.616 0.766 . . . . 0.0 109.37 177.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 64.8 tp -166.08 117.39 1.03 Allowed 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 105.33 -2.1 . . . . 0.0 105.33 -179.536 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.4 pt -53.87 132.9 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 C-N-CA 123.092 0.557 . . . . 0.0 112.497 179.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 31.8 p -111.75 90.18 3.27 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.293 0.568 . . . . 0.0 111.529 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.4 p -83.94 101.39 11.66 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.483 0.713 . . . . 0.0 109.503 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.9 p -139.89 101.5 4.19 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.27 0 CA-C-O 122.829 1.299 . . . . 0.0 109.822 179.988 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.217 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.0 pp -95.19 99.1 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.563 1.472 0 CA-C-O 123.247 1.499 . . . . 0.0 108.761 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -166.35 -31.28 0.03 OUTLIER 'General case' 0 CA--C 1.567 1.615 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 175.59 -65.15 0.1 OUTLIER Glycine 0 CA--C 1.543 1.811 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -177.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.5 t -78.31 85.82 4.43 Favored 'General case' 0 N--CA 1.492 1.667 1 CA-C-N 136.325 8.693 . . . . 0.0 108.694 -178.45 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.07 -51.48 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 CA-C-N 114.465 -1.243 . . . . 0.0 110.967 -176.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.5 tppt? -73.2 -67.74 0.55 Allowed 'General case' 0 CA--C 1.567 1.607 0 C-N-CA 124.311 1.045 . . . . 0.0 110.173 177.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 tt -153.68 113.74 3.91 Favored 'General case' 0 CA--C 1.553 1.071 0 N-CA-C 101.524 -3.509 . . . . 0.0 101.524 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.311 11.0 tp -50.47 102.77 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 N-CA-C 115.14 1.533 . . . . 0.0 115.14 -177.634 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.7 p -148.42 52.8 1.0 Allowed 'General case' 0 CA--C 1.562 1.409 0 CA-C-N 114.37 -1.286 . . . . 0.0 112.984 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 74.3 p -96.95 111.24 23.54 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 121.326 -0.859 . . . . 0.0 109.653 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.6 m -141.67 117.35 10.36 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-N 113.894 -1.503 . . . . 0.0 112.427 -179.944 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.308 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -94.21 70.09 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 124.046 0.841 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -144.2 120.79 11.1 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.716 0.807 . . . . 0.0 109.159 -178.685 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -83.24 0.69 Allowed Glycine 0 N--CA 1.48 1.62 0 CA-C-N 116.343 -0.39 . . . . 0.0 112.789 -179.9 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.2 t -78.91 90.77 4.74 Favored 'General case' 0 N--CA 1.493 1.706 1 CA-C-N 134.052 7.66 . . . . 0.0 107.841 -178.323 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 149.52 -53.68 0.51 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -75.23 -68.86 0.51 Allowed 'General case' 0 CA--C 1.566 1.561 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.481 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.8 tp -167.04 117.82 0.89 Allowed 'General case' 0 CA--C 1.554 1.107 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -53.95 133.73 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -179.599 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 29.5 p -111.72 99.2 7.96 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 121.181 0.515 . . . . 0.0 110.624 -177.936 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 67.2 p -77.56 102.74 7.11 Favored 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 123.467 0.707 . . . . 0.0 110.437 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.5 p -140.84 102.26 4.24 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.036 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 CA-C-O 122.992 1.377 . . . . 0.0 111.855 -179.9 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.199 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.54 106.89 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 . . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 77.7 m95 -138.1 107.46 6.13 Favored 'General case' 0 CA--C 1.555 1.14 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.897 -179.039 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.43 84.43 0.83 Allowed Glycine 0 N--CA 1.484 1.877 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.2 t -78.77 88.65 4.62 Favored 'General case' 0 N--CA 1.494 1.771 1 CA-C-N 135.162 8.165 . . . . 0.0 108.152 -178.262 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.62 -50.57 0.62 Allowed Glycine 0 CA--C 1.548 2.111 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 -176.133 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -74.9 -70.81 0.39 Allowed 'General case' 0 CA--C 1.563 1.461 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.256 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.5 tp -169.08 117.88 0.67 Allowed 'General case' 0 CA--C 1.554 1.103 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 179.796 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.254 2.6 pp -50.94 135.91 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.454 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 19.9 p -123.88 109.17 13.27 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.345 0.593 . . . . 0.0 111.47 -177.268 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 77.1 p -81.7 100.02 9.25 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.273 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 26.4 m -79.37 -52.13 8.49 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -179.275 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.186 0 CA-C-O 124.366 2.031 . . . . 0.0 110.333 179.946 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.208 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.52 98.5 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 . . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 41.0 m95 -100.34 107.54 19.34 Favored 'General case' 0 CA--C 1.553 1.087 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.851 -178.32 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.1 84.69 0.79 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 178.271 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.5 t -78.5 88.89 4.45 Favored 'General case' 0 N--CA 1.494 1.728 1 CA-C-N 136.843 8.929 . . . . 0.0 108.524 -177.817 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.57 -52.96 0.68 Allowed Glycine 0 CA--C 1.548 2.133 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.644 -176.493 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -72.81 -62.27 1.51 Allowed 'General case' 0 CA--C 1.563 1.466 0 C-N-CA 123.916 0.886 . . . . 0.0 110.837 178.233 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.6 tt -158.73 110.04 2.14 Favored 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 -179.775 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.7 pp -55.65 115.62 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -179.512 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 80.0 m -89.7 82.66 6.27 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 121.796 0.808 . . . . 0.0 112.265 -177.771 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 66.7 p -84.39 108.25 17.11 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.571 0.749 . . . . 0.0 109.737 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.1 m -141.02 116.18 9.92 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.898 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 124.181 1.943 . . . . 0.0 110.739 179.963 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.16 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -84.24 78.51 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 124.093 0.871 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 8.0 m0 -125.01 116.92 22.9 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.839 0.855 . . . . 0.0 109.898 -177.701 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.96 80.77 1.09 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 111.745 -0.542 . . . . 0.0 111.745 -179.241 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.7 t -79.11 89.59 4.83 Favored 'General case' 0 N--CA 1.493 1.706 1 CA-C-N 134.808 8.004 . . . . 0.0 107.845 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.31 -52.19 0.56 Allowed Glycine 0 CA--C 1.546 2.004 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.054 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -75.13 -70.12 0.43 Allowed 'General case' 0 CA--C 1.564 1.486 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 177.357 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 66.8 tp -167.96 118.04 0.8 Allowed 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.899 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 pt -52.4 133.12 14.5 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 N-CA-C 113.032 0.753 . . . . 0.0 113.032 -179.673 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 24.0 p -114.88 86.93 2.54 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 121.551 0.691 . . . . 0.0 111.724 -177.906 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 77.5 p -81.65 -57.13 3.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.712 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 60.3 p -98.66 -49.32 4.65 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 124.429 1.092 . . . . 0.0 113.356 -179.454 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 124.321 2.01 . . . . 0.0 111.403 -179.827 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.18 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 39.4 mm -113.65 96.15 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 N-CA-C 104.817 -2.29 . . . . 0.0 104.817 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 95.8 m95 -145.46 152.85 40.44 Favored 'General case' 0 CA--C 1.558 1.268 0 CA-C-N 114.7 -1.136 . . . . 0.0 110.439 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.23 -85.7 1.21 Allowed Glycine 0 CA--C 1.542 1.765 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.077 178.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.6 t -74.63 86.58 2.13 Favored 'General case' 0 N--CA 1.493 1.698 1 CA-C-N 136.582 8.81 . . . . 0.0 109.564 -177.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.32 -54.93 0.45 Allowed Glycine 0 CA--C 1.546 1.983 0 CA-C-N 114.115 -1.402 . . . . 0.0 109.885 -176.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -77.21 -68.81 0.58 Allowed 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 123.726 0.811 . . . . 0.0 109.94 177.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 60.0 tp -160.14 113.0 2.09 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 106.082 -1.821 . . . . 0.0 106.082 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -52.87 142.02 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.977 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 -179.168 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.7 m -82.08 95.22 7.39 Favored 'General case' 0 CA--C 1.557 1.223 0 C-N-CA 123.835 0.854 . . . . 0.0 110.102 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 69.9 p -70.15 105.82 3.06 Favored 'General case' 0 N--CA 1.492 1.671 0 CA-C-N 114.926 -1.034 . . . . 0.0 111.207 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.0 p -141.8 102.71 4.21 Favored 'General case' 0 N--CA 1.483 1.218 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 -179.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.294 0 CA-C-O 124.158 1.932 . . . . 0.0 110.836 -179.913 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.199 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.8 mm -126.42 113.02 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 104.806 -2.294 . . . . 0.0 104.806 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -66.18 134.02 51.86 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -89.35 -108.63 1.19 Allowed Glycine 0 CA--C 1.539 1.591 0 CA-C-N 116.381 -0.372 . . . . 0.0 113.692 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.4 t -74.86 86.75 2.25 Favored 'General case' 0 N--CA 1.493 1.693 1 CA-C-N 136.865 8.939 . . . . 0.0 109.587 -176.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 144.12 -51.99 0.62 Allowed Glycine 0 CA--C 1.547 2.053 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.391 -176.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -77.31 -67.12 0.75 Allowed 'General case' 0 CA--C 1.562 1.435 0 C-N-CA 123.856 0.862 . . . . 0.0 110.014 178.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -159.97 108.01 1.7 Allowed 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 105.646 -1.983 . . . . 0.0 105.646 -179.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.265 2.0 pp -51.43 138.75 8.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 N-CA-C 115.932 1.827 . . . . 0.0 115.932 -178.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.2 m -82.01 94.42 7.16 Favored 'General case' 0 CA--C 1.556 1.199 0 CA-C-O 122.008 0.909 . . . . 0.0 110.076 -179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.7 p -68.84 114.01 6.79 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.776 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 m -143.33 116.27 8.83 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 124.179 1.943 . . . . 0.0 110.698 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.231 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.24 106.87 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 65.5 m95 -138.34 129.8 27.63 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 115.197 -0.91 . . . . 0.0 109.854 -178.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.44 -112.14 0.69 Allowed Glycine 0 CA--C 1.537 1.422 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.5 t -78.8 87.45 4.68 Favored 'General case' 0 N--CA 1.495 1.78 1 CA-C-N 137.737 9.335 . . . . 0.0 109.273 -177.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.21 -51.67 0.75 Allowed Glycine 0 CA--C 1.548 2.098 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.989 -176.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 2.3 tppp? -70.13 -64.32 0.91 Allowed 'General case' 0 CA--C 1.562 1.419 0 C-N-CA 124.108 0.963 . . . . 0.0 111.427 178.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 50.0 tp -153.6 104.52 2.73 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 105.366 -2.086 . . . . 0.0 105.366 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.252 1.7 pp -53.63 113.44 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.992 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 79.0 m -89.91 81.44 6.3 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-O 121.8 0.81 . . . . 0.0 111.682 -178.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.9 p -83.79 106.91 15.85 Favored 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 123.559 0.744 . . . . 0.0 110.307 -179.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 27.1 m -81.86 -53.53 6.09 Favored 'General case' 0 N--CA 1.498 1.943 0 CA-C-O 118.5 -0.762 . . . . 0.0 112.909 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.218 0 CA-C-O 124.109 1.909 . . . . 0.0 110.608 179.874 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.234 0.246 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 10.8 tp -149.91 112.58 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 80.5 m95 -131.89 122.13 25.16 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.183 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 108.22 -88.74 0.54 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -178.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.9 t -59.53 87.99 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.776 0 CA-C-N 125.413 3.733 . . . . 0.0 111.695 -175.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 150.43 -54.54 0.48 Allowed Glycine 0 CA--C 1.557 2.682 0 CA-C-N 111.728 -2.487 . . . . 0.0 108.325 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.1 ttmt -79.03 -71.16 0.45 Allowed 'General case' 0 CA--C 1.572 1.79 0 C-N-CA 124.523 1.129 . . . . 0.0 109.317 177.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.2 tp -139.34 102.23 4.44 Favored 'General case' 0 CA--C 1.562 1.406 0 N-CA-C 104.523 -2.399 . . . . 0.0 104.523 178.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.3 pp -33.28 142.14 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.508 2.432 0 N-CA-C 119.804 3.261 . . . . 0.0 119.804 -177.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -87.28 80.2 8.29 Favored 'General case' 0 CA--C 1.563 1.465 0 C-N-CA 123.773 0.829 . . . . 0.0 111.804 -179.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 66.9 p -116.01 102.52 9.72 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.7 p -140.43 102.32 4.31 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.261 0 CA-C-O 124.159 1.933 . . . . 0.0 108.979 -179.934 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.184 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.7 mm -112.67 99.31 8.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 32.3 m95 -93.46 109.5 21.09 Favored 'General case' 0 CA--C 1.554 1.13 0 CA-C-N 114.865 -1.061 . . . . 0.0 109.065 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 98.24 101.95 2.22 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.0 t -79.64 88.96 5.12 Favored 'General case' 0 N--CA 1.493 1.699 1 CA-C-N 136.211 8.641 . . . . 0.0 108.125 -178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.56 -50.86 0.67 Allowed Glycine 0 CA--C 1.548 2.104 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.44 -176.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -75.65 -66.92 0.72 Allowed 'General case' 0 CA--C 1.563 1.452 0 C-N-CA 124.028 0.931 . . . . 0.0 108.768 177.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 53.3 tp -167.29 116.44 0.83 Allowed 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.269 2.1 pp -54.92 132.42 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.974 0 N-CA-C 114.335 1.235 . . . . 0.0 114.335 -178.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 72.0 m -96.39 94.75 7.61 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 123.753 0.821 . . . . 0.0 110.817 -177.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.8 p -71.76 104.44 3.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.979 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.6 p -141.69 103.65 4.4 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 -178.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 122.821 1.296 . . . . 0.0 112.646 -179.87 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.157 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -99.56 79.18 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 CA-C-O 122.116 0.96 . . . . 0.0 110.859 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 43.7 p-90 -148.41 62.83 1.09 Allowed 'General case' 0 CA--C 1.561 1.378 0 C-N-CA 124.206 1.003 . . . . 0.0 111.18 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 59.22 76.54 0.21 Allowed Glycine 0 N--CA 1.49 2.277 0 CA-C-O 119.038 -0.868 . . . . 0.0 113.613 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 37.6 t -78.8 87.23 4.68 Favored 'General case' 0 N--CA 1.494 1.739 1 CA-C-N 137.246 9.112 . . . . 0.0 109.37 -177.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.22 -49.22 0.78 Allowed Glycine 0 CA--C 1.546 2.004 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.867 -176.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -73.43 -68.26 0.51 Allowed 'General case' 0 CA--C 1.561 1.383 0 C-N-CA 124.074 0.95 . . . . 0.0 109.94 178.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 61.7 tp -162.65 110.04 1.28 Allowed 'General case' 0 CA--C 1.552 1.047 0 N-CA-C 105.958 -1.867 . . . . 0.0 105.958 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.9 pt -51.5 133.41 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.0 0 N-CA-C 114.198 1.184 . . . . 0.0 114.198 -179.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 85.7 m -103.0 83.82 2.27 Favored 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 121.612 0.72 . . . . 0.0 112.181 -178.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.0 t -161.82 122.25 2.61 Favored 'General case' 0 N--CA 1.485 1.289 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 22.9 m -84.69 -54.05 4.97 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 114.852 -1.067 . . . . 0.0 112.805 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.218 0 CA-C-O 124.18 1.943 . . . . 0.0 108.488 179.774 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.209 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 pp -132.1 105.4 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -159.1 -64.67 0.08 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.471 0.708 . . . . 0.0 112.252 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 119.91 -90.36 0.47 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.631 -0.588 . . . . 0.0 111.631 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.2 t -79.05 86.16 4.91 Favored 'General case' 0 N--CA 1.496 1.834 1 CA-C-N 134.426 7.83 . . . . 0.0 107.955 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.4 -53.5 0.44 Allowed Glycine 0 CA--C 1.546 2.0 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -175.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -76.12 -69.44 0.5 Allowed 'General case' 0 CA--C 1.564 1.518 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.8 tp -165.12 117.28 1.18 Allowed 'General case' 0 CA--C 1.553 1.063 0 N-CA-C 104.445 -2.428 . . . . 0.0 104.445 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.3 pt -52.9 132.07 15.04 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 N-CA-C 113.063 0.764 . . . . 0.0 113.063 -179.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 22.6 p -113.65 89.3 3.05 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 121.283 0.564 . . . . 0.0 110.648 -178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.9 p -81.93 102.64 11.04 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.544 0.737 . . . . 0.0 110.129 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.4 p -140.4 102.31 4.31 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-O 124.306 2.003 . . . . 0.0 110.756 -179.836 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.2 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 40.9 mm -117.19 99.19 7.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 N-CA-C 104.68 -2.341 . . . . 0.0 104.68 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 97.2 m95 -137.68 94.37 2.9 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 173.25 -84.72 0.08 OUTLIER Glycine 0 CA--C 1.537 1.468 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 35.6 t -74.23 85.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.654 1 CA-C-N 136.689 8.859 . . . . 0.0 109.563 -177.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 152.31 -54.65 0.46 Allowed Glycine 0 CA--C 1.546 1.989 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.092 -176.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 81.8 tttt -76.95 -68.51 0.6 Allowed 'General case' 0 CA--C 1.564 1.511 0 C-N-CA 123.674 0.789 . . . . 0.0 110.1 178.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.1 tt -157.91 111.13 2.45 Favored 'General case' 0 CA--C 1.555 1.165 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -51.77 140.28 6.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.1 0 N-CA-C 114.773 1.397 . . . . 0.0 114.773 -178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 8.1 m -82.86 82.48 8.13 Favored 'General case' 0 N--CA 1.488 1.465 0 CA-C-O 121.728 0.775 . . . . 0.0 110.215 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 9.6 t -103.79 140.74 37.22 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 124.478 1.111 . . . . 0.0 111.716 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 57.5 p -97.14 92.58 6.11 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.277 0 CA-C-O 122.961 1.362 . . . . 0.0 109.932 -179.594 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.23 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.6 tp -143.13 106.46 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 53.7 p-90 -158.0 137.56 11.99 Favored 'General case' 0 CA--C 1.556 1.191 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.348 -177.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -108.48 -110.18 3.37 Favored Glycine 0 N--CA 1.481 1.641 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 178.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 35.0 t -74.44 86.28 2.03 Favored 'General case' 0 N--CA 1.493 1.686 1 CA-C-N 135.826 8.466 . . . . 0.0 109.375 -177.211 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.74 -51.37 0.56 Allowed Glycine 0 CA--C 1.547 2.068 0 CA-C-N 114.363 -1.29 . . . . 0.0 110.008 -176.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -77.18 -71.83 0.38 Allowed 'General case' 0 CA--C 1.563 1.467 0 C-N-CA 124.137 0.975 . . . . 0.0 108.765 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 45.6 tp -160.85 107.55 1.48 Allowed 'General case' 0 CA--C 1.557 1.215 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.2 pp -44.74 142.64 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -178.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 10.5 m -86.82 71.32 10.33 Favored 'General case' 0 CA--C 1.566 1.583 0 CA-C-O 122.112 0.958 . . . . 0.0 112.139 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 22.2 p -148.09 -65.74 0.25 Allowed 'General case' 0 CA--C 1.56 1.353 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 67.8 p -81.86 -46.57 13.94 Favored 'General case' 0 CA--C 1.567 1.599 0 C-N-CA 123.976 0.91 . . . . 0.0 111.955 178.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 CA-C-O 123.072 1.415 . . . . 0.0 108.362 179.262 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.155 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -90.14 78.01 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 CA-C-O 122.183 0.992 . . . . 0.0 110.751 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.5 m0 -92.47 120.59 33.11 Favored 'General case' 0 CA--C 1.555 1.138 0 C-N-CA 123.732 0.813 . . . . 0.0 110.66 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.77 91.89 1.76 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.286 -1.926 . . . . 0.0 108.286 178.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 41.3 t -98.32 84.68 3.27 Favored 'General case' 0 N--CA 1.489 1.516 1 CA-C-N 148.35 14.159 . . . . 0.0 108.562 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 134.63 -48.29 0.95 Allowed Glycine 0 CA--C 1.548 2.135 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.986 -177.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 36.9 mtmm -69.64 -60.53 2.26 Favored 'General case' 0 CA--C 1.561 1.379 0 C-N-CA 124.39 1.076 . . . . 0.0 112.311 178.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 55.5 tp -159.55 104.36 1.6 Allowed 'General case' 0 N--CA 1.482 1.135 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -178.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -52.67 137.06 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.082 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 4.1 m -77.07 88.02 3.57 Favored 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 122.167 0.984 . . . . 0.0 112.622 -178.238 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 41.5 p -131.59 101.11 5.36 Favored 'General case' 0 CA--C 1.554 1.124 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 13.3 p -137.94 103.03 4.86 Favored 'General case' 0 N--CA 1.485 1.291 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.267 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 122.881 1.324 . . . . 0.0 112.635 -179.834 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.164 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 7.0 tp -143.35 105.07 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 50.7 m95 -106.98 84.19 1.94 Allowed 'General case' 0 CA--C 1.556 1.189 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.44 96.48 0.2 Allowed Glycine 0 N--CA 1.478 1.477 0 N-CA-C 109.046 -1.621 . . . . 0.0 109.046 -178.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 43.3 t -77.66 85.5 3.98 Favored 'General case' 0 N--CA 1.492 1.659 1 CA-C-N 135.938 8.517 . . . . 0.0 108.679 -178.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.36 -51.32 0.52 Allowed Glycine 0 CA--C 1.549 2.174 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.24 -176.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.82 -65.48 0.79 Allowed 'General case' 0 CA--C 1.566 1.57 0 C-N-CA 124.044 0.937 . . . . 0.0 109.488 178.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 59.0 tp -155.41 112.09 3.21 Favored 'General case' 0 CA--C 1.553 1.06 0 N-CA-C 102.203 -3.258 . . . . 0.0 102.203 178.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.312 10.9 tp -46.45 103.74 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.221 0 N-CA-C 115.91 1.819 . . . . 0.0 115.91 -177.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 15.0 p -150.05 58.24 0.97 Allowed 'General case' 0 CA--C 1.56 1.356 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.369 179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 56.3 p -67.37 -52.6 38.03 Favored 'General case' 0 N--CA 1.497 1.88 0 N-CA-C 114.3 1.222 . . . . 0.0 114.3 179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 91.7 m -100.43 -58.4 1.91 Allowed 'General case' 0 CA--C 1.566 1.571 0 C-N-CA 124.398 1.079 . . . . 0.0 109.605 178.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.23 0 CA-C-O 124.133 1.921 . . . . 0.0 109.441 179.267 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.228 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.8 mm -122.09 107.82 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 N-CA-C 104.329 -2.471 . . . . 0.0 104.329 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -126.38 117.8 23.71 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 114.98 -88.95 0.49 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -178.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . 0.444 ' SG ' ' C ' ' A' ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 44.9 t -67.95 83.57 0.21 Allowed 'General case' 0 N--CA 1.491 1.622 0 CA-C-N 123.88 3.036 . . . . 0.0 109.663 -177.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.15 -50.15 0.7 Allowed Glycine 0 CA--C 1.554 2.512 0 CA-C-N 114.047 -1.433 . . . . 0.0 110.0 -175.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 49.0 tptt -75.28 -67.11 0.69 Allowed 'General case' 0 CA--C 1.566 1.571 0 CA-C-N 118.079 0.94 . . . . 0.0 110.544 178.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 57.2 tp -157.33 111.52 2.65 Favored 'General case' 0 CA--C 1.555 1.144 0 N-CA-C 104.571 -2.381 . . . . 0.0 104.571 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.259 2.0 pp -52.36 125.54 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 N-CA-C 115.607 1.706 . . . . 0.0 115.607 -177.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 6.1 p -92.57 76.03 5.06 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.915 0.886 . . . . 0.0 110.526 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.2 t -154.95 -36.28 0.09 Allowed 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 114.534 1.309 . . . . 0.0 114.534 -179.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 41.8 p -101.9 96.0 6.75 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.2 0 CA-C-O 124.374 2.035 . . . . 0.0 110.698 -179.733 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.184 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.47 109.54 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 61.6 m95 -125.03 108.15 11.54 Favored 'General case' 0 CA--C 1.554 1.113 0 C-N-CA 124.085 0.954 . . . . 0.0 109.37 -178.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 147.41 -103.33 0.27 Allowed Glycine 0 N--CA 1.48 1.568 0 N-CA-C 108.744 -1.742 . . . . 0.0 108.744 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . 0.464 ' SG ' ' C ' ' A' ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 42.0 t -67.56 84.04 0.18 Allowed 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 123.846 3.021 . . . . 0.0 109.275 -177.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.47 -51.56 0.6 Allowed Glycine 0 CA--C 1.554 2.492 0 CA-C-N 113.756 -1.566 . . . . 0.0 109.536 -175.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -76.14 -68.16 0.61 Allowed 'General case' 0 CA--C 1.564 1.502 0 C-N-CA 123.987 0.915 . . . . 0.0 110.894 177.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.4 tt -153.39 110.83 3.51 Favored 'General case' 0 CA--C 1.554 1.127 0 N-CA-C 104.329 -2.471 . . . . 0.0 104.329 -179.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.5 pp -52.83 119.52 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 N-CA-C 114.881 1.438 . . . . 0.0 114.881 -178.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 7.6 p -89.52 81.46 6.53 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 124.008 0.923 . . . . 0.0 111.221 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 74.1 p -82.95 103.5 12.45 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 123.561 0.744 . . . . 0.0 109.89 -179.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.6 p -139.53 102.31 4.43 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 -179.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.189 0 CA-C-O 124.141 1.924 . . . . 0.0 111.025 -179.964 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.19 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.4 tp -154.42 116.72 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 1.3 p-90 -73.14 145.75 46.16 Favored 'General case' 0 CA--C 1.562 1.441 0 N-CA-C 113.569 0.951 . . . . 0.0 113.569 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.39 -62.53 0.99 Allowed Glycine 0 N--CA 1.485 1.95 0 N-CA-C 116.7 1.44 . . . . 0.0 116.7 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 24.7 t -77.71 89.52 3.98 Favored 'General case' 0 N--CA 1.493 1.686 1 CA-C-N 136.061 8.573 . . . . 0.0 110.619 -176.217 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.07 -49.94 0.78 Allowed Glycine 0 CA--C 1.544 1.857 0 CA-C-N 114.772 -1.103 . . . . 0.0 111.504 -177.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 76.8 tttt -71.17 -64.75 0.85 Allowed 'General case' 0 CA--C 1.564 1.503 0 CA-C-N 118.066 0.933 . . . . 0.0 110.381 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -156.41 109.68 2.65 Favored 'General case' 0 CA--C 1.55 0.957 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.9 pt -57.53 127.78 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 71.1 m -95.38 89.67 5.53 Favored 'General case' 0 CA--C 1.551 1.005 0 CA-C-O 121.623 0.725 . . . . 0.0 111.791 -177.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 82.7 p -71.01 -54.51 10.96 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 42.4 p -102.97 -55.17 2.47 Favored 'General case' 0 CA--C 1.564 1.498 0 C-N-CA 124.495 1.118 . . . . 0.0 112.122 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.195 0 CA-C-O 124.351 2.024 . . . . 0.0 110.227 -179.948 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.216 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -92.9 80.04 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 124.044 0.84 . . . . 0.0 110.797 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 11.1 m95 -85.85 95.96 9.61 Favored 'General case' 0 N--CA 1.486 1.36 0 CA-C-O 122.064 0.935 . . . . 0.0 109.725 -179.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.44 -80.55 0.18 Allowed Glycine 0 CA--C 1.54 1.618 0 N-CA-C 107.965 -2.054 . . . . 0.0 107.965 -178.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 34.2 t -77.64 88.61 3.93 Favored 'General case' 0 N--CA 1.491 1.591 1 CA-C-N 135.961 8.528 . . . . 0.0 108.941 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 141.81 -51.68 0.68 Allowed Glycine 0 CA--C 1.547 2.038 0 CA-C-N 114.71 -1.132 . . . . 0.0 111.075 -176.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 42.3 tptt -72.17 -64.07 1.02 Allowed 'General case' 0 CA--C 1.564 1.496 0 C-N-CA 123.905 0.882 . . . . 0.0 110.73 178.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 56.7 tp -157.46 109.01 2.33 Favored 'General case' 0 CA--C 1.553 1.065 0 N-CA-C 104.052 -2.573 . . . . 0.0 104.052 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.7 tp -55.46 109.15 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.504 2.255 0 C-N-CA 123.381 0.673 . . . . 0.0 112.044 -178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . 0.274 2.1 p -106.43 64.65 0.66 Allowed 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 114.548 1.314 . . . . 0.0 114.548 -177.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 46.9 p -89.54 102.57 15.25 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.0 p -139.71 101.56 4.23 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 -179.362 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 124.185 1.945 . . . . 0.0 109.028 -179.941 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.215 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -94.46 75.02 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 CA-C-O 122.401 1.096 . . . . 0.0 111.572 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . 0.3 28.5 p-90 -146.67 -101.38 0.09 Allowed 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 -179.811 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.61 -64.51 1.32 Allowed Glycine 0 CA--C 1.55 2.224 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 177.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.2 t -74.9 84.17 2.21 Favored 'General case' 0 N--CA 1.494 1.728 1 CA-C-N 135.766 8.439 . . . . 0.0 109.281 -178.001 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.76 -53.69 0.44 Allowed Glycine 0 CA--C 1.547 2.05 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -176.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -77.8 -70.93 0.45 Allowed 'General case' 0 CA--C 1.564 1.494 0 C-N-CA 123.854 0.861 . . . . 0.0 109.403 177.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.2 tt -158.74 112.65 2.42 Favored 'General case' 0 CA--C 1.556 1.178 0 N-CA-C 105.031 -2.211 . . . . 0.0 105.031 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 4.5 pt -50.26 142.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 115.917 1.821 . . . . 0.0 115.917 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 9.8 m -85.39 89.36 7.66 Favored 'General case' 0 CA--C 1.559 1.321 0 CA-C-O 121.874 0.845 . . . . 0.0 109.651 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 68.3 p -74.95 105.65 6.08 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 123.693 0.797 . . . . 0.0 110.419 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.6 p -140.24 102.34 4.34 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 124.311 2.005 . . . . 0.0 110.662 -179.866 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.143 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -92.11 61.83 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.903 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 99.3 m95 -150.78 88.78 1.5 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 179.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.99 90.72 0.16 Allowed Glycine 0 N--CA 1.489 2.171 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -178.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.1 t -98.4 83.54 3.06 Favored 'General case' 0 N--CA 1.489 1.513 1 CA-C-N 147.854 13.934 . . . . 0.0 107.856 -178.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.2 -46.89 0.93 Allowed Glycine 0 CA--C 1.549 2.177 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.798 -177.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -69.45 -65.33 0.73 Allowed 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 124.541 1.137 . . . . 0.0 111.385 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.3 tp -155.28 105.85 2.53 Favored 'General case' 0 CA--C 1.555 1.135 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -179.128 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 7.9 tp -52.22 129.52 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.295 0 C-N-CA 123.907 0.883 . . . . 0.0 112.993 179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 2.7 m -75.32 71.08 2.28 Favored 'General case' 0 CA--C 1.569 1.697 0 CA-C-O 122.231 1.015 . . . . 0.0 113.503 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 70.0 p -143.65 144.39 31.87 Favored 'General case' 0 CA--C 1.56 1.334 0 C-N-CA 125.054 1.341 . . . . 0.0 108.396 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 58.3 p -83.23 93.13 7.61 Favored 'General case' 0 N--CA 1.489 1.5 0 CA-C-O 122.33 1.062 . . . . 0.0 109.508 179.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.204 0 CA-C-N 114.127 -1.397 . . . . 0.0 109.847 -179.625 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.23 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.1 mm -93.61 95.19 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 N-CA-C 105.977 -1.86 . . . . 0.0 105.977 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 12.9 m0 -99.77 88.27 3.76 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.68 -177.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.44 84.08 0.04 OUTLIER Glycine 0 N--CA 1.48 1.628 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.7 t -78.29 88.39 4.33 Favored 'General case' 0 N--CA 1.495 1.785 1 CA-C-N 134.772 7.987 . . . . 0.0 108.219 -178.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.27 -51.11 0.56 Allowed Glycine 0 CA--C 1.546 2.026 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 -176.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 39.6 ttmt -75.79 -70.74 0.42 Allowed 'General case' 0 CA--C 1.563 1.458 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.374 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.0 tt -166.51 116.54 0.94 Allowed 'General case' 0 CA--C 1.554 1.098 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.254 2.1 pp -52.83 134.0 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.071 0 N-CA-C 113.456 0.91 . . . . 0.0 113.456 -179.378 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 27.4 p -115.62 101.0 8.45 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.126 0.489 . . . . 0.0 111.537 -177.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 67.6 p -81.17 100.34 9.03 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 179.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 17.4 p -139.59 103.34 4.67 Favored 'General case' 0 N--CA 1.484 1.234 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 -178.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.302 0 CA-C-O 122.901 1.334 . . . . 0.0 112.52 -179.833 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.232 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -90.16 76.11 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 CA-C-O 122.165 0.983 . . . . 0.0 111.31 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 77.8 m95 -129.24 97.89 4.73 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 105.216 -2.142 . . . . 0.0 105.216 179.794 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 103.26 110.13 3.42 Favored Glycine 0 CA--C 1.54 1.636 0 N-CA-C 106.357 -2.697 . . . . 0.0 106.357 -176.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.7 t -79.13 89.23 4.83 Favored 'General case' 0 N--CA 1.492 1.665 1 CA-C-N 135.539 8.336 . . . . 0.0 108.427 -177.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.42 -53.2 0.53 Allowed Glycine 0 CA--C 1.544 1.858 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -176.596 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -75.42 -68.78 0.53 Allowed 'General case' 0 CA--C 1.563 1.461 0 C-N-CA 123.616 0.766 . . . . 0.0 109.37 177.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 64.8 tp -166.08 117.39 1.03 Allowed 'General case' 0 CA--C 1.552 1.041 0 N-CA-C 105.33 -2.1 . . . . 0.0 105.33 -179.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.4 pt -53.87 132.9 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.101 0 C-N-CA 123.092 0.557 . . . . 0.0 112.497 179.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 31.8 p -111.75 90.18 3.27 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.293 0.568 . . . . 0.0 111.529 -178.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 73.4 p -83.94 101.39 11.66 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 123.483 0.713 . . . . 0.0 109.503 -179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.9 p -139.89 101.5 4.19 Favored 'General case' 0 N--CA 1.484 1.228 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.27 0 CA-C-O 122.829 1.299 . . . . 0.0 109.822 179.988 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.217 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.0 pp -95.19 99.1 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.563 1.472 0 CA-C-O 123.247 1.499 . . . . 0.0 108.761 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 62.2 p-90 -166.35 -31.28 0.03 OUTLIER 'General case' 0 CA--C 1.567 1.615 0 N-CA-C 115.667 1.728 . . . . 0.0 115.667 -178.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 175.59 -65.15 0.1 OUTLIER Glycine 0 CA--C 1.543 1.811 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -177.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.5 t -78.31 85.82 4.43 Favored 'General case' 0 N--CA 1.492 1.667 1 CA-C-N 136.325 8.693 . . . . 0.0 108.694 -178.45 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.07 -51.48 0.49 Allowed Glycine 0 CA--C 1.549 2.196 0 CA-C-N 114.465 -1.243 . . . . 0.0 110.967 -176.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 17.5 tppt? -73.2 -67.74 0.55 Allowed 'General case' 0 CA--C 1.567 1.607 0 C-N-CA 124.311 1.045 . . . . 0.0 110.173 177.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.0 tt -153.68 113.74 3.91 Favored 'General case' 0 CA--C 1.553 1.071 0 N-CA-C 101.524 -3.509 . . . . 0.0 101.524 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.311 11.0 tp -50.47 102.77 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.258 0 N-CA-C 115.14 1.533 . . . . 0.0 115.14 -177.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 20.7 p -148.42 52.8 1.0 Allowed 'General case' 0 CA--C 1.562 1.409 0 CA-C-N 114.37 -1.286 . . . . 0.0 112.984 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 74.3 p -96.95 111.24 23.54 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 121.326 -0.859 . . . . 0.0 109.653 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.6 m -141.67 117.35 10.36 Favored 'General case' 0 N--CA 1.486 1.374 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.269 0 CA-C-N 113.894 -1.503 . . . . 0.0 112.427 -179.944 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.308 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pp -94.21 70.09 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 124.046 0.841 . . . . 0.0 111.319 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -144.2 120.79 11.1 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.716 0.807 . . . . 0.0 109.159 -178.685 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 97.86 -83.24 0.69 Allowed Glycine 0 N--CA 1.48 1.62 0 CA-C-N 116.343 -0.39 . . . . 0.0 112.789 -179.9 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.2 t -78.91 90.77 4.74 Favored 'General case' 0 N--CA 1.493 1.706 1 CA-C-N 134.052 7.66 . . . . 0.0 107.841 -178.323 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 149.52 -53.68 0.51 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -75.23 -68.86 0.51 Allowed 'General case' 0 CA--C 1.566 1.561 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.481 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.8 tp -167.04 117.82 0.89 Allowed 'General case' 0 CA--C 1.554 1.107 0 N-CA-C 104.27 -2.492 . . . . 0.0 104.27 -179.98 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -53.95 133.73 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.04 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -179.599 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 29.5 p -111.72 99.2 7.96 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 121.181 0.515 . . . . 0.0 110.624 -177.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 67.2 p -77.56 102.74 7.11 Favored 'General case' 0 N--CA 1.487 1.4 0 C-N-CA 123.467 0.707 . . . . 0.0 110.437 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 16.5 p -140.84 102.26 4.24 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 -179.036 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 CA-C-O 122.992 1.377 . . . . 0.0 111.855 -179.9 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.199 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.54 106.89 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 . . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 77.7 m95 -138.1 107.46 6.13 Favored 'General case' 0 CA--C 1.555 1.14 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.897 -179.039 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.43 84.43 0.83 Allowed Glycine 0 N--CA 1.484 1.877 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 38.2 t -78.77 88.65 4.62 Favored 'General case' 0 N--CA 1.494 1.771 1 CA-C-N 135.162 8.165 . . . . 0.0 108.152 -178.262 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 145.62 -50.57 0.62 Allowed Glycine 0 CA--C 1.548 2.111 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 -176.133 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.4 tptt -74.9 -70.81 0.39 Allowed 'General case' 0 CA--C 1.563 1.461 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.256 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 67.5 tp -169.08 117.88 0.67 Allowed 'General case' 0 CA--C 1.554 1.103 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 179.796 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.254 2.6 pp -50.94 135.91 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.505 2.278 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.454 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 19.9 p -123.88 109.17 13.27 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 121.345 0.593 . . . . 0.0 111.47 -177.268 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 77.1 p -81.7 100.02 9.25 Favored 'General case' 0 N--CA 1.488 1.428 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 179.273 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 26.4 m -79.37 -52.13 8.49 Favored 'General case' 0 N--CA 1.497 1.906 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -179.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.186 0 CA-C-O 124.366 2.031 . . . . 0.0 110.333 179.946 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.208 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.52 98.5 7.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 . . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 41.0 m95 -100.34 107.54 19.34 Favored 'General case' 0 CA--C 1.553 1.087 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.851 -178.32 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.1 84.69 0.79 Allowed Glycine 0 N--CA 1.484 1.84 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 178.271 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.5 t -78.5 88.89 4.45 Favored 'General case' 0 N--CA 1.494 1.728 1 CA-C-N 136.843 8.929 . . . . 0.0 108.524 -177.817 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.57 -52.96 0.68 Allowed Glycine 0 CA--C 1.548 2.133 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.644 -176.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -72.81 -62.27 1.51 Allowed 'General case' 0 CA--C 1.563 1.466 0 C-N-CA 123.916 0.886 . . . . 0.0 110.837 178.233 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.6 tt -158.73 110.04 2.14 Favored 'General case' 0 N--CA 1.482 1.175 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 -179.775 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.7 pp -55.65 115.62 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.499 2.016 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -179.512 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 80.0 m -89.7 82.66 6.27 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 121.796 0.808 . . . . 0.0 112.265 -177.771 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 66.7 p -84.39 108.25 17.11 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 123.571 0.749 . . . . 0.0 109.737 -179.877 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.1 m -141.02 116.18 9.92 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.898 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 124.181 1.943 . . . . 0.0 110.739 179.963 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.16 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.6 pp -84.24 78.51 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 124.093 0.871 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . . . . . . . . . 8.0 m0 -125.01 116.92 22.9 Favored 'General case' 0 N--CA 1.484 1.228 0 C-N-CA 123.839 0.855 . . . . 0.0 109.898 -177.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 84.96 80.77 1.09 Allowed Glycine 0 N--CA 1.484 1.895 0 N-CA-C 111.745 -0.542 . . . . 0.0 111.745 -179.241 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' BCX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.7 t -79.11 89.59 4.83 Favored 'General case' 0 N--CA 1.493 1.706 1 CA-C-N 134.808 8.004 . . . . 0.0 107.845 -178.422 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.31 -52.19 0.56 Allowed Glycine 0 CA--C 1.546 2.004 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -176.054 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -75.13 -70.12 0.43 Allowed 'General case' 0 CA--C 1.564 1.486 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 177.357 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 66.8 tp -167.96 118.04 0.8 Allowed 'General case' 0 CA--C 1.553 1.077 0 N-CA-C 104.772 -2.307 . . . . 0.0 104.772 179.899 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 12.5 pt -52.4 133.12 14.5 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.073 0 N-CA-C 113.032 0.753 . . . . 0.0 113.032 -179.673 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . . . . . . . . . 24.0 p -114.88 86.93 2.54 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 121.551 0.691 . . . . 0.0 111.724 -177.906 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 77.5 p -81.65 -57.13 3.59 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 113.625 0.972 . . . . 0.0 113.625 -179.712 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 60.3 p -98.66 -49.32 4.65 Favored 'General case' 0 N--CA 1.489 1.513 0 C-N-CA 124.429 1.092 . . . . 0.0 113.356 -179.454 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.259 0 CA-C-O 124.321 2.01 . . . . 0.0 111.403 -179.827 . . . . . . . . 0 0 . 1 stop_ save_